Nanosonics Ltd 2023 AR2
The report highlights Nanosonics' financial and operational achievements for the 2023 fiscal year, including a 38% increase in total revenue to $166.0 million and a significant rise in profit before tax to $21.6 million. The company expanded its global trophon installed base by 9% to 32,450 units, protecting approximately 26 million patients annually from ultrasound probe cross-contamination. Nanosonics also advanced its ESG agenda, conducting its first carbon footprint measurement and achieving ISO 27001 certification for information security. Additionally, the company continued to invest in research and development, particularly for its upcoming CORIS endoscope reprocessing platform.
Company: Nanosonics Ltd
Sector: Health Care
Country: Australia
Year: 2023
Type: AR2
Pages: 112
Nanosonics Ltd
Annual Report
The report highlights Nanosonics' financial and operational achievements for the 2023 fiscal year, including a 38% increase in total revenue to $166.0 million and a significant rise in profit before tax to $21.6 million. The company expanded its global trophon installed base by 9% to 32,450 units, protecting approximately 26 million patients annually from ultrasound probe cross-contamination. Nanosonics also advanced its ESG agenda, conducting its first carbon footprint measurement and achieving ISO 27001 certification for information security. Additionally, the company continued to invest in research and development, particularly for its upcoming CORIS endoscope reprocessing platform.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees